Pathogenetic approach to the treatment of patients with benign prostatic hyperplasia and chronic prostatitis: modern strategies. A review
Abstract
The recent increase in the global incidence of benign prostatic hyperplasia (BPH) over the past three decades, combined with the anticipated aging of the population, underscores the urgent need for effective and pathogenetically grounded non-surgical treatment methods. Research has established that chronic inflammation is not merely an accompanying factor but a critical component in the pathogenesis of BPH. Specifically, inflammatory cells and the pro-inflammatory cytokines they produce initiate a series of pathological responses, including tissue remodeling and fibrosis, while also promoting the proliferation of both stromal and epithelial cells within the prostate. Furthermore, inflammatory cytokines have been shown to disrupt hormonal balance in the prostate gland, fostering tissue remodeling and hyperplastic growth. This inflammatory response in BPH often leads to a state of relative hypoxia, driven by the increased oxygen demands of proliferating cells. An additional insult is oxidative stress; the interplay of reduced antioxidant capacity, excessive reactive oxygen species, and chronic inflammation creates a vicious cycle that exacerbates hyperplastic changes. Standard therapies currently employed for BPH primarily focus on symptom relief without directly addressing oxidative stress or inflammation. Given the significant role chronic inflammation plays in BPH pathogenesis, an anti-inflammatory treatment strategy is particularly relevant. One promising approach involves…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.